Mutant-Allele Tumor Heterogeneity (MATH) in head, neck squamous cell carcinoma patients is effective marker, along with HPV status, of improved…
source : http://www.sciencedaily.com/releases/2014/02/140220102601.htm
source : http://www.sciencedaily.com/releases/2014/02/140220102601.htm
source : http://www.sciencedaily.com/releases/2014/01/140129134909.htm
source : http://www.sciencedaily.com/releases/2014/01/140127093134.htm
source : http://www.sciencedaily.com/releases/2013/11/131107094416.htm
source : http://www.sciencedaily.com/releases/2014/01/140123142041.htm
"Over the past decades, we’ve had great success in treating breast cancer, and the 15-year survival rate is now 77 percent," said study leader David J. Brenner, PhD, director of CUMC’s Center for Radiological Research and the Higgins Professor of Radiation Biophysics. "Unfortunately, breast cancer survivors have a several times higher risk of developing cancer in their other breast, compared with healthy women of the same age." "While drugs such as tamoxifen and aromatase inhibitors can reduce the risk somewhat, at least for women with estrogen receptor-positive tumors, the long-term risks of a second breast cancer in the unaffected breast remain high. …
source : http://www.sciencedaily.com/releases/2013/12/131211185046.htm
The independent Data and Safety Monitoring Committee overseeing the trial recommended to the National Cancer Institute (NCI), part of NIH, that the study results be made public because a recent planned interim analysis showed prolongation in overall survival. Full details from this early analysis will be presented at a scientific meeting in 2014 and in a peer-reviewed publication. The study enrolled 790 men with metastatic prostate cancer between July 2006 and November 2012 in a trial known as E3805. …
"Patients with metastatic or recurrent breast cancer, as well as those with locally advanced disease that cannot be surgically removed, have no curative options," said John R. …
"We achieved up to 60 fold higher levels of endoxifen compared to endoxifen levels achieved with the standard dose of tamoxifen," says Matthew Goetz, M.D., a Mayo Clinic oncologist and lead author of the study. "We have seen evidence for tumor regression in patients who had failed standard hormonal therapies including aromatase inhibitors, fulvestrant and tamoxifen. This is an exciting first step in the development of this drug." Tamoxifen is a hormonal therapy that has been used for over 40 years to reduce the risk of breast cancer recurrence and to prevent breast cancer. …